Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

us recorded revenue during the first quarter of 2008 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the first quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $2.5 million of research revenue on reimbursed research and development costs.

Amicus today reiterated its guidance for 2008 cash burn of $40 million to $60 million. The Company also stated that it does not expect to raise cash from any equity financings in 2008.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in tables 2 and 3, and are primarily due to:

-- Pre-tax stock compensation expense

-- Pre-tax charges for preferred stock accretion

-- Pre-tax charges for changes in the fair value of warrant liability

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... -- ValGenesis Inc., the market leader in enterprise Validation Lifecycle ... its Service Organization Controls 2 (SOC 2) examination under ... the period of January 1 st  2014  through ... Logo - http://photos.prnewswire.com/prnh/20150401/195954LOGO ... The SOC 2 examination is performed in accordance with ...
(Date:4/1/2015)... IRVINE, CA (PRWEB) April 01, 2015 ... in Personalized Medicine , presented two scientific posters ... City, Utah, last week. The four-day event was hosted ... 2,000 genetic specialists dedicated to educating genetic and genomic ... Biosciences presented Genetics and Insomnia: Study on the Role ...
(Date:4/1/2015)... 2015  Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology, presented data on the ... 2015 Experimental Biology conference in Boston, ... an ideal extension of Organovo,s capabilities to 3D ... in pharmaceutical research," said Keith Murphy , ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Holomic is ... can read both chromatographic and fluorescent rapid tests with ... of high performance, quantitative readers and is already selling ... HRDR-400 is a first of its kind offering for ... instrument. , Dr. Neven Karlovac, CEO of Holomic ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2
... Calif., Nov. 6 Pathwork Diagnostics, a,genomics-based diagnostics ... University School of Medicine has initiated an,investigational study ... new,genomics-based test is designed to help determine a ... study makes it one of the first,institutions in ...
... Nov. 6 Centocor,Inc., Schering-Plough Corporation, and ... estimated one million patients have now been,treated ... (TNF)-alpha therapy worldwide. In fact, REMICADE has ... all other anti-TNF-alpha agents,combined. REMICADE was the ...
... Particulate Sensor for Airborne Biological Threats Receives Government ... ... Nov. 6 ICx Technologies, a developer of,advanced technology solutions ... procure its AirSentinel(R) ambient aerosol,sensors for detection of airborne biological ...
Cached Biology Technology:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 2Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 3Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 2REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 3REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 5REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 6REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 8REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 9REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 10REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 11REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 12ICx Awarded Department of Defense Contract for AirSentinel Monitors 2
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/16/2015)... Germany , March 16, 2015 ... Identification Systems GmbH will present groundbreaking innovations in ... Hanover, Germany .      ... DERMALOG,s latest biometric innovation is well at the ... next generation e-gate made in Germany ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... Texas Researchers at The University of Texas at Austin have ... that may improve the efficacy of vaccines for diseases such as ... E. coli , which were described in a paper published this ... new class of biological "adjuvants" that is poised to transform vaccine ...
... with the likelihood that people take on managerial responsibilities, ... The study, published online in Leadership Quarterly ... sequence associated with the tendency for individuals to occupy ... international research team, which included academics from Harvard, NYU, ...
... third most common family of epidermal growth factor receptor ... is known about cancers harboring these mutations aside from ... impairing the development of effective targeted therapies. A recent ... International Association for the Study of Lung Cancer,s (IASLC) ...
Cached Biology News:Designer bacteria may lead to better vaccines 2Designer bacteria may lead to better vaccines 3Born to lead? Leadership can be an inherited trait, study finds 2
... culture scale-up, these culture chambers produce cell ... 9 range and are useful alternatives ... • High mechanical • strength and structural ... shipping • Certified nonpyrogenic and sterilized by ...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
... EnVision™ G|2 Doublestain System is a ... visualization kit. The kit is intended ... simultaneous detection of two different antigens ... compatible with suitably diluted rabbit and ...
... enzyme exists predominantly as XDH which converts ... critical plasma antioxidant. During ischemia, XDH ... producing XO by oxidation of essential sulfhydryl ... of the amino-terminus. AO has a ...
Biology Products: